Fig. 7. IL-4-induced BMDMs show reduced necrosis and apoptosis following TAA-ALI.
IL-4 or LPS + IFN-γ was used to treat GFP-labeled BMDMs, and the cells were transplanted by intraperitoneal injection (IP) or tail vein injection (IV). A Representative images of macrophage movement after transplantation using an in vivo imaging system. Next, we performed the following experimental treatments before TAA-ALI (200 mg/kg) was established: macrophage depletion by clodronate liposome injection (DM), transplantation of LPS + IFN-γ-induced BMDMs (MLPS+IFN-γ), and transplantation of IL-4-induced BMDMs (MIL-4). The results of the TAA-ALI groups are shown here, and the control (PBS-treated) groups are shown in S4. B Serum ALT (left panel) and AST (right panel) levels in each group. C Representative H&E staining of the liver. D Representative TUNEL (green fluorescence) staining of the liver with DAPI counterstaining (blue fluorescence) and (E) quantification. F mRNA expression (Tnfa, Il1b, Il6) in liver tissue was detected by RT–PCR. The average target gene/GAPDH ratios of different experimental groups relative to the control group are given. (G, H) Representative F4/80 and (H) Ly6G IHC staining images of liver tissue from each group. I Quantification of G and H. All data shown represent n = 8–10 mice per group. All results are representative of at least three independent experiments. Values are presented as the mean ± SD. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.